Skip to content

Novel Exhaled Breath Aerosol Collection Devices in Patients With Lower Respiratory Tract Infection - a Performance and Acceptability Study

Novel Exhaled Breath Aerosol Collection Devices in Patients With Lower Respiratory Tract Infection - a Performance and Acceptability Study (Acronym: AeroCAP)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06668883
Acronym
AeroCAP
Enrollment
23
Registered
2024-11-01
Start date
2024-11-13
Completion date
2025-05-21
Last updated
2025-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lower Respiratory Tract Infection (LRTI), Pneumonia

Keywords

Respiratory Tract Infections, Pneumonia, Communicable Diseases, Infections, Breath

Brief summary

This study will assess the performance of two novel breath collection devices and their subsequent detection of respiratory pathogens compared to sputum samples in patients with lower respiratory tract infections.

Interventions

PROCEDURESputum collection for molecular analysis

Sputum collection to be used with syndromic multiplex PCR testing

DEVICEBreath and cough collection for molecular analysis

Breath and cough collection with two proprietary devices to be used with syndromic multiplex PCR testing

Sponsors

University Hospital, Basel, Switzerland
CollaboratorOTHER
Avelo AG
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Able to understand the scope of the study and provide written informed consent * Age \>18 years * Speaking German or English * Health status (assessed by study personnel at local site) well enough to use the breath collection devices * Willing to provide all three study samples (sputum and two breath samples) required for the study * Clinical diagnosis of a lower respiratory tract infection (LRTI) defined as: (i) New infiltrate (chest X-ray, ultrasound, or CT scan), and (ii) at least one clinical symptom suggestive of LRTI (fever ≥38°C, chills, new or worsening cough, new or worsening sputum production, new or worsening dyspnea, tachypnoea, chest pain)

Exclusion criteria

* Patients for whom the collection of all three study specimens within 48 hours of initiating antibiotic treatment is not feasible * Patients with known cystic fibrosis or bronchiectasis * Critically ill patients at the discretion of the investigator * Patients on oxygen supplementation with a face mask, high-flow-oxygen, non-invasive or mechanical ventilation; oxygen supplementation via nasal cannula will be permitted. * Patients with proven acute pulmonary embolism * Patients with best supportive care * Patients with severe hypoxemia (SpO2 \<88%) despite oxygen supplementation * Hospitalization within the last 14 days prior to admission

Design outcomes

Primary

MeasureTime frameDescription
Pathogen Concordance6 monthsOverall percent agreement, negative percent agreement, and positive percent agreement between syndromic respiratory multiplex PCR results from breath samples and sputum samples.

Secondary

MeasureTime frameDescription
Usability2 days after sample collectionAssess the usability of the breath collection devices and sampling procedures by gathering user feedback from patients using a multiple choice questionnaire. Ease-of-use questions will be assessed using a 5-point difficulty rating system. Additionally, the investigators will assess the proportion of participants able to complete the breath collections without any deviations.
Expanded user feedback2 days after sample collectionA subset of patients and clinicians will be observed during the breath collection process. The investigators will gather the proportion of participants making errors during breath collections and documenting any common difficulties. User feedback data from a subset of patients and clinicians will be gathered via semi-structured interviews. Data will be assessed qualitatively for reported acceptability and user preferences.
Rates of indeterminate breath results6 monthsProportion of breath samples with invalid and/or indeterminate syndromic respiratory multiplex PCR results

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 12, 2026